Clinical Trial Update: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two dose levels of imetelstat in intermediate/High-risk myelofibrosis patients previously treated with a JAK inhibitor has completed, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Imetelstat (imetelstat)

Snippet

Sponsor: Geron Corporation | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2021-09-14